2. >>R&D

AstraZeneca Hopes To Differentiate Benralizumab On Efficacy, Dosing Convenience

 
• By Joseph Haas

AstraZeneca PLC is keeping a tight lid on Phase III data for its biologic for severe asthma, benralizumab, other than to say it met its primary endpoint in a pair of pivotal trials – but the pharma hopes to offer differentiating efficacy from GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd. biologics already approved for this indication when it unveils the full datasets at a scientific meeting later this year.

On May 17, AstraZeneca announced that benralizumab achieved statistically significant reductions in annual exacerbation rates compared to placebo in patients with severe asthma with eosinophilic inflammation in the Phase III SIROCCO and CALIMA studies. Patients in SIROCCO (n=1,206) and CALIMA (n=1,305) were uncontrolled on inhaled corticosteroids and/or long-acting beta agonist (LABA) therapy, with or without oral corticosteroids or other therapies.

The company plans to file benralizumab, in-licensed by MedImmune LLC from a subsidiary of Kyowa Hakko Kirin Co. Ltd

More from Clinical Trials

More from R&D

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.